[go: up one dir, main page]

MA33051B1 - Variants de liaison anti-albumine serique ameliores - Google Patents

Variants de liaison anti-albumine serique ameliores

Info

Publication number
MA33051B1
MA33051B1 MA34104A MA34104A MA33051B1 MA 33051 B1 MA33051 B1 MA 33051B1 MA 34104 A MA34104 A MA 34104A MA 34104 A MA34104 A MA 34104A MA 33051 B1 MA33051 B1 MA 33051B1
Authority
MA
Morocco
Prior art keywords
serum albumin
contrasts
albumin enhancer
antagonist
antagonist serum
Prior art date
Application number
MA34104A
Other languages
Arabic (ar)
English (en)
Inventor
Angelis Elena De
Carolyn Enever
Haiqun Liu
Christopher Plummer
Oliver Schon
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MA33051B1 publication Critical patent/MA33051B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention porte sur des variants améliorés du domaine variable unique DOM7h-14 de l'immunoglobuline anti-albumine sérique, ainsi que des ligands et des conjugués de médicaments contenant de tels variants, des compositions, des acides nucléiques, des vecteurs et des hôtes.
MA34104A 2009-02-19 2010-02-17 Variants de liaison anti-albumine serique ameliores MA33051B1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US15374609P 2009-02-19 2009-02-19
US16398709P 2009-03-27 2009-03-27
US24713609P 2009-09-30 2009-09-30
PCT/EP2010/052008 WO2010094723A2 (fr) 2009-02-19 2010-02-17 Variants de liaison anti-albumine sérique améliorés

Publications (1)

Publication Number Publication Date
MA33051B1 true MA33051B1 (fr) 2012-02-01

Family

ID=42634270

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34104A MA33051B1 (fr) 2009-02-19 2010-02-17 Variants de liaison anti-albumine serique ameliores

Country Status (25)

Country Link
US (3) US9534043B2 (fr)
EP (3) EP3656788A3 (fr)
JP (2) JP5759391B2 (fr)
KR (1) KR101819754B1 (fr)
CN (1) CN102405233B (fr)
AR (1) AR075505A1 (fr)
AU (1) AU2010215482B2 (fr)
BR (1) BRPI1013341B1 (fr)
CA (2) CA3079184A1 (fr)
CL (1) CL2011002025A1 (fr)
CO (1) CO6410311A2 (fr)
DO (1) DOP2011000266A (fr)
EA (1) EA028178B1 (fr)
ES (2) ES2774192T3 (fr)
HK (1) HK1247944A1 (fr)
IL (1) IL214480A0 (fr)
MA (1) MA33051B1 (fr)
MX (1) MX2011008749A (fr)
NZ (1) NZ595242A (fr)
PE (1) PE20120001A1 (fr)
SG (1) SG173489A1 (fr)
TW (1) TW201042039A (fr)
UY (1) UY32450A (fr)
WO (1) WO2010094723A2 (fr)
ZA (1) ZA201105657B (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA021146B1 (ru) * 2009-03-27 2015-04-30 Глаксо Груп Лимитед Продукты слияния и конъюгаты лекарственных средств
WO2011008814A2 (fr) 2009-07-14 2011-01-20 Immune Tolerance Institute, Inc., A California Not-For-Profit Corporation Mesure multiplexée d'adn endogène et exogène
SG10201406063XA (en) * 2009-09-30 2014-11-27 Glaxo Group Ltd Drug fusions and conjugates with extended half life
BR112012010114A2 (pt) * 2009-10-27 2017-08-08 Glaxo Group Ltd domínio variável único de imunoglobulina, ligante multiespecífico, antagonista, uso do antagonista, método para tratamento e/ou profilaxia de uma condição inflamatória em um paciente, ácido nucleico, vetor, e, célula hospedeira.
EP2571900A1 (fr) * 2010-05-20 2013-03-27 Glaxo Group Limited Variants de liaison anti-sérum-albumine améliorés
WO2012020143A1 (fr) * 2010-08-13 2012-02-16 Glaxo Group Limited Variants de liaison anti-sérum-albumine améliorés
EP2853542A1 (fr) * 2010-11-24 2015-04-01 Glaxo Group Limited Protéines multispécifique se liant à un antigène et ciblant HGF
EP2646467A2 (fr) 2010-12-01 2013-10-09 Glaxo Group Limited Domaines variables améliorés à liaison unique d'anti-albumine sérique
EP2670778A1 (fr) 2011-02-02 2013-12-11 Glaxo Group Limited Nouvelles protéines de liaison à un antigène
AU2017268394A1 (en) 2016-05-18 2019-01-03 Modernatx, Inc. Polynucleotides encoding relaxin
ES3015094T3 (en) 2017-06-05 2025-04-29 Numab Therapeutics AG Anti-hsa antibodies
WO2018224439A1 (fr) * 2017-06-05 2018-12-13 Numab Innovation Ag Nouveaux anticorps anti-hsa
AR131869A1 (es) 2023-02-17 2025-05-07 Ablynx Nv POLIPÉPTIDOS QUE SE UNEN AL RECEPTOR DE Fc NEONATAL

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
US20100081792A1 (en) * 2001-06-28 2010-04-01 Smithkline Beecham Corporation Ligand
US9321832B2 (en) * 2002-06-28 2016-04-26 Domantis Limited Ligand
AU2003244817B2 (en) 2002-06-28 2010-08-26 Domantis Limited Antigen-binding immunoglobulin single variable domains and dual-specific constructs
US20060002935A1 (en) 2002-06-28 2006-01-05 Domantis Limited Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
SI1737962T1 (sl) 2004-03-24 2011-01-31 Domantis Ltd Univerzalni signalni peptid GAS1
AU2005250216B2 (en) 2004-06-01 2009-12-10 Domantis Limited Bispecific fusion antibodies with enhanced serum half-life
EP1841796A2 (fr) 2004-12-02 2007-10-10 Domantis Limited Anticorps bispecifiques de domaine visant l'albumine serique et glp-1 ou pyy
KR20080090414A (ko) * 2005-12-06 2008-10-08 도만티스 리미티드 세포 표면 표적에 대한 결합 특이성이 있는 이중 특이성리간드 및 이의 사용방법
CA2640066A1 (fr) 2006-01-24 2007-08-02 Roland Beckmann Proteines de fusion contenant des jonctions naturelles
GB0621513D0 (en) 2006-10-30 2006-12-06 Domantis Ltd Novel polypeptides and uses thereof
CA2688434A1 (fr) 2007-06-06 2008-12-11 Domantis Limited Polypeptides, domaines variables d'anticorps et antagonistes
GB0724331D0 (en) 2007-12-13 2008-01-23 Domantis Ltd Compositions for pulmonary delivery
BRPI0823231A2 (pt) 2008-11-26 2015-06-16 Glaxo Group Ltd Domínio variável único da imunoglobulina anti-interleucina-13 (il-13), antagonista da interleucina-13 (il-13), uso da antagonista, método para tratar e/ou prevenir uma condição mediada pela il-13 em um paciente, dispositivo de dispensação pulmonar contendo o antagonista, ligando específico duplo, ácido nucléico isolado ou recombinante, vetor, célula hospedeira, método para produzir polipeptídeo, e, proteína de fusão.
EA022925B1 (ru) * 2009-02-19 2016-03-31 Глаксо Груп Лимитед Улучшенные полипептиды, вариабельные домены антител и антагонисты против tnfr1
PE20120170A1 (es) 2009-02-19 2012-03-21 Glaxo Group Ltd Variantes de union a anti-albumina de suero mejoradas
EP2453920A2 (fr) * 2009-07-16 2012-05-23 Glaxo Group Limited Antagonistes, utilisations, et procédés pour inhiber partiellement le tnfr1
SG10201406063XA (en) * 2009-09-30 2014-11-27 Glaxo Group Ltd Drug fusions and conjugates with extended half life
CA2796932A1 (fr) * 2010-04-21 2011-10-27 Glaxo Group Limited Domaines de liaison

Also Published As

Publication number Publication date
CA3079184A1 (fr) 2010-08-26
PE20120001A1 (es) 2012-02-12
WO2010094723A2 (fr) 2010-08-26
CO6410311A2 (es) 2012-03-30
JP2015204831A (ja) 2015-11-19
AU2010215482B2 (en) 2014-02-13
KR20110127223A (ko) 2011-11-24
AU2010215482A1 (en) 2011-08-25
US20170298121A1 (en) 2017-10-19
EP3330287A1 (fr) 2018-06-06
BRPI1013341B1 (pt) 2021-09-08
US10696738B2 (en) 2020-06-30
NZ595242A (en) 2013-11-29
JP2012517820A (ja) 2012-08-09
EP3330287B1 (fr) 2019-12-18
HK1247944A1 (en) 2018-10-05
US20200283512A1 (en) 2020-09-10
EP2398826B1 (fr) 2017-10-25
EP3656788A2 (fr) 2020-05-27
BRPI1013341A2 (pt) 2016-10-11
SG173489A1 (en) 2011-09-29
CA2767752C (fr) 2020-07-07
CN102405233B (zh) 2014-11-26
CN102405233A (zh) 2012-04-04
CL2011002025A1 (es) 2012-04-09
US9534043B2 (en) 2017-01-03
DOP2011000266A (es) 2011-12-31
AR075505A1 (es) 2011-04-06
ES2774192T3 (es) 2020-07-17
EP3656788A3 (fr) 2020-07-29
JP5759391B2 (ja) 2015-08-05
UY32450A (es) 2010-09-30
ES2655071T3 (es) 2018-02-16
MX2011008749A (es) 2011-09-06
US20110305696A1 (en) 2011-12-15
EA028178B1 (ru) 2017-10-31
WO2010094723A3 (fr) 2011-04-21
CA2767752A1 (fr) 2010-08-26
EA201171068A1 (ru) 2012-02-28
JP6100315B2 (ja) 2017-03-22
KR101819754B1 (ko) 2018-01-18
EP2398826A2 (fr) 2011-12-28
TW201042039A (en) 2010-12-01
ZA201105657B (en) 2012-04-25
IL214480A0 (en) 2011-09-27

Similar Documents

Publication Publication Date Title
MA33052B1 (fr) Variants de liaison anti-albumine sérique améliorés
MA33051B1 (fr) Variants de liaison anti-albumine serique ameliores
CY1119454T1 (el) Αντισωματα εναντι cd38 για τη θεραπεια του πολλαπλου μυελωματος
IN2012DN00640A (fr)
EA201291009A1 (ru) Улучшенные связывающие варианты против сывороточного альбумина
MA35659B1 (fr) Protéine de liaison à un antigène et son utilisation comme produit d'adressage pour le traitement du cancer
UA106194C2 (ru) Диагностика и лечение рака с применением антитела к ereg
MA37840A3 (fr) Immunoconjugués comprenant des anticorps anti-cd79b
CY1116578T1 (el) Αναστολεις της bromodomain και χρησεις αυτων
EA200702048A1 (ru) Фармакокинетически улучшенные соединения
EP2152290A4 (fr) Méthodes pour administrer des anticorps anti-il-5
SG10201405377XA (en) Compositions and methods for antibodies targeting complement protein c5
EA201390785A1 (ru) Антитела, обладающие низкой аффинностью к рецепторам гематоэнцефалического барьера, и их применения
MA39378A1 (fr) Anticorps igf-1r et son utilisation comme véhicule d'adressage pour le traitement du cancer
EA201170441A1 (ru) Терапевтические противовирусные пептиды
MX2010005871A (es) Anticuerpos al antigeno de pcrv de pseudomonas aeruginosa.
ATE472998T1 (de) Kationische liposomale zubereitungen zur behandlung von rheumatoider arthritis
EA201170344A1 (ru) Азаиндольные ингибиторы iap
UA107836C2 (uk) Метод лікування хвороби альцгеймера
MA35281B1 (fr) Dosage et administration d'anticorps anti-erbb3 en combinaison avec le paclitaxel pour le traitement de cancers gynécologiques
EA201390116A1 (ru) Улучшенные связывающие варианты против сывороточного альбумина
MA34487B1 (fr) Compositions d'anticorps anti-vegfr-3.
CR20110472A (es) Variantes de unión a anti-albumina de suero mejoradas
CY1116251T1 (el) Συστηματα michael ως αναστολεις τρανσγλουταμινασων
MA37838A1 (fr) Immunoconjugués comprenant des anticorps anti-cd22